Patents by Inventor Zhi-Liang Chu

Zhi-Liang Chu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100068700
    Abstract: The present invention relates to methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual. Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. Agonists of GPR119 receptor promote bone formation in an individual.
    Type: Application
    Filed: April 10, 2007
    Publication date: March 18, 2010
    Inventors: Zhi-Liang Chu, James M. Leonard
  • Publication number: 20090297537
    Abstract: The present invention concerns combination of an amount of a BRS-3 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the BRS-3 agonist alone and by the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing obesity and diabetes and conditions related thereto and conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
    Type: Application
    Filed: April 26, 2006
    Publication date: December 3, 2009
    Inventors: Zhi Liang Chu, James N. Leonard
  • Publication number: 20090270422
    Abstract: The present invention relates to the use of GPR119 receptor agonists for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. The present invention further relates to the use of a GPR119 receptor agonist in combination with a dipeptidyl peptidase IV (DPP-IV) inhibitor for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. A GPR119 receptor agonist and the combination of a GPR119 receptor agonist and a DPP-IV inhibitor promote bone formation in an individual.
    Type: Application
    Filed: April 10, 2007
    Publication date: October 29, 2009
    Inventors: Zhi-Liang Chu, James N. Leonard, Juerg Lehmann, Robert M. Jones
  • Publication number: 20090253153
    Abstract: The present invention relates to methods of using GPR119 receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY, such as conditions modulated by stimulation of NPY Y2 receptor (Y2R). Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition modulated by PYY, such as a condition modulated by stimulation of Y2R. Conditions modulated by PYY such as may be a condition modulated by stimulation of Y2R include bone-related conditions, metabolic disorders, angiogenesis-related conditions, ischemia-related conditions, convulsive disorders, malabsorptive disorders, cancers, and inflammatory disorders.
    Type: Application
    Filed: February 23, 2009
    Publication date: October 8, 2009
    Applicant: ARENA PHARMACEUTICALS, INC
    Inventors: ZHI-LIANG CHU, James N. Leonard, Robert M. Jones
  • Publication number: 20080312277
    Abstract: The present invention relates to a method for identifying a glycemic stabilizing compound by: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is modulated, where a modulation in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound. In addition, the invention relates to a method for identifying a glycemic stabilizing compound, comprising: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is increased, wherein an increase in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound. Further, the invention relates to a method for identifying a glycemic stabilizing compound, comprising: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is decreased, wherein a decrease in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound.
    Type: Application
    Filed: November 1, 2005
    Publication date: December 18, 2008
    Inventors: James N. Leonard, Zhi Liang Chu, Marc A. Bruce, P. Douglas Boatman
  • Publication number: 20070077602
    Abstract: The present invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR35, and b) determining whether GPR35 functionality is increased, wherein an increase in GPR35 functionality is indicative of the candidate compound being a metabolic stabilizing compound. The invention further relates to a method for treating or preventing a metabolic-related disorder, comprising administering to an individual in need thereof an effective amount of a GPR35 modulator.
    Type: Application
    Filed: December 13, 2006
    Publication date: April 5, 2007
    Inventors: James Leonard, Zhi Liang Chu
  • Publication number: 20070072803
    Abstract: The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
    Type: Application
    Filed: November 22, 2006
    Publication date: March 29, 2007
    Applicant: Arena Pharmaceuticals
    Inventors: Zhi-Liang Chu, James Leonard, Hussien Al-Shamma, Robert Jones
  • Publication number: 20070072804
    Abstract: The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
    Type: Application
    Filed: November 22, 2006
    Publication date: March 29, 2007
    Applicant: Arena Pharmaceuticals
    Inventors: Zhi-Liang Chu, James Leonard, Hussien Al-Shamma, Robert Jones
  • Publication number: 20060154866
    Abstract: The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
    Type: Application
    Filed: January 9, 2006
    Publication date: July 13, 2006
    Inventors: Zhi-Liang Chu, James Leonard, Hussien Al-Shamma, Robert Jones
  • Patent number: 6953691
    Abstract: The invention provides isolated nucleic acid molecules encoding PAAD-domain containing polypeptides and functional fragments thereof, including fragments containing PAAD domains, NB-ARC domains and LRR domains, encoded polypeptides, and antibodies. Also provided are methods of identifying polypeptides and agents that associate with a PAAD-domain containing polypeptide or fragment thereof, or that alter an association of a PAAD domain-containing polypeptides. Further provided are methods of identifying agents that modulate PAAD domain-mediated inhibition of NF?B activity, or modulate an activity of an NB-ARC domain of a PAAD domain-containing polypeptide. Also provided are methods of modulating NF?B transcriptional activity in a cell, and methods of altering expression of a PAAD domain-containing polypeptide in a cell.
    Type: Grant
    Filed: February 17, 2004
    Date of Patent: October 11, 2005
    Assignee: The Burnham Institute
    Inventors: John C Reed, Adam Godzik, Zhi-Liang Chu, Krzysztof Pawlowski, Loredana Fiorentino, Maria Eugenia Ariza, Christian Stehlik
  • Publication number: 20040142374
    Abstract: The invention provides isolated nucleic acid molecules encoding PAAD-domain containing polypeptides and functional fragments thereof, including fragments containing PAAD domains, NB-ARC domains and LRR domains, encoded polypeptides, and antibodies. Also provided are methods of identifying polypeptides and agents that associate with a PAAD-domain containing polypeptide or fragment thereof, or that alter an association of a PAAD domain-containing polypeptides. Further provided are methods of identifying agents that modulate PAAD domain-mediated inhibition of NFkB activity, or modulate an activity of an NB-ARC domain of a PAAD domain-containing polypeptide. Also provided are methods of modulating NFkB transcriptional activity in a cell, and methods of altering expression of a PAAD domain-containing polypeptide in a cell.
    Type: Application
    Filed: February 17, 2004
    Publication date: July 22, 2004
    Applicant: THE BURNHAM INSTITUTE.
    Inventors: John C. Reed, Adam Godzik, Zhi-Liang Chu, Krzysztof Pawlowski, Loredana Fiorentino, Maria Eugenia Ariza, Christian Stehlik
  • Publication number: 20030139588
    Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is unknown, and to mutated (non-endogenous) versions of the human GPCRs for evidence of constitutive activity.
    Type: Application
    Filed: November 26, 2001
    Publication date: July 24, 2003
    Inventors: Ruoping Chen, Zhi Liang Chu, Huong T. Dang, Kevin P. Lowitz, Cameron Pride
  • Publication number: 20030077699
    Abstract: The invention provides isolated nucleic acid molecules encoding PAAD-domain containing polypeptides and functional fragments thereof, including fragments containing PAAD domains, NB-ARC domains and LRR domains, encoded polypeptides, and antibodies. Also provided are methods of identifying polypeptides and agents that associate with a PAAD-domain containing polypeptide or fragment thereof, or that alter an association of a PAAD domain-containing polypeptides. Further provided are methods of identifying agents that modulate PAAD domain-mediated inhibition of NF&kgr;B activity, or modulate an activity of an NB-ARC domain of a PAAD domain-containing polypeptide. Also provided are methods of modulating NF&kgr;B transcriptional activity in a cell, and methods of altering expression of a PAAD domain-containing polypeptide in a cell.
    Type: Application
    Filed: September 25, 2001
    Publication date: April 24, 2003
    Inventors: John C. Reed, Adam Godzik, Zhi-Liang Chu, Krzysztof Pawlowski, Loredana Fiorentino, Maria Eugenia Ariza, Christian Stehlik
  • Publication number: 20020193584
    Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is unknown, and to mutated (non-endogenous) versions of the human GPCRs for evidence of constitutive activity.
    Type: Application
    Filed: November 26, 2001
    Publication date: December 19, 2002
    Inventors: Ruoping Chen, Zhi Liang Chu, Huong T. Dang, Kevin P. Lowitz, Cameron Pride